Levo-t is a drug owned by Cediprof Inc. It is protected by 1 US drug patent filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Mar 30, 2020. Details of Levo-t's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US6399101 | Stable thyroid hormone preparations and method of making same |
Mar, 2020
(4 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Levo-t is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Levo-t's family patents as well as insights into ongoing legal events on those patents.
Levo-t's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Levo-t's generic launch date based on the expiry of its last outstanding patent is estimated to be Mar 30, 2020 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Levo-t Generic API suppliers:
Levothyroxine Sodium is the generic name for the brand Levo-t. 16 different companies have already filed for the generic of Levo-t, with Mylan having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Levo-t's generic
Alternative Brands for Levo-t
There are several other brand drugs using the same active ingredient (Levothyroxine Sodium) as Levo-t. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | ||
|---|---|---|---|
| Azurity |
| ||
| Fresenius Kabi Usa |
| ||
| Genus Lifesciences |
| ||
| Hikma |
| ||
| Ibsa |
| ||
| Inst Biochimique |
| ||
| King Pharms |
| ||
| Mylan |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Levothyroxine Sodium, Levo-t's active ingredient. Check the complete list of approved generic manufacturers for Levo-t
About Levo-t
Levo-T is a drug owned by Cediprof Inc. Levo-T uses Levothyroxine Sodium as an active ingredient. Levo-T was launched by Cediprof Inc in 2002.
Approval Date:
Levo-t was approved by FDA for market use on 01 March, 2002.
Active Ingredient:
Levo-t uses Levothyroxine Sodium as the active ingredient. Check out other Drugs and Companies using Levothyroxine Sodium ingredient
Dosage:
Levo-t is available in tablet form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET | Prescription | ORAL |
| 0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET | Prescription | ORAL |
| 0.3MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET | Prescription | ORAL |
| 0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET | Prescription | ORAL |
| 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET | Prescription | ORAL |
| 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET | Prescription | ORAL |
| 0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET | Prescription | ORAL |
| 0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET | Prescription | ORAL |
| 0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET | Prescription | ORAL |
| 0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET | Prescription | ORAL |
| 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET | Prescription | ORAL |